177Lu-DOTA-EB-TATE is a therapeutic agent based on the peptide octreotate that uses an Evans blue structure to bind albumin to improve the pharmacokinetics and pharmacodynamics.
177Lu-DOTA-EB-TATE is a modified molecule that brings some biological advantages but above all provides an alternative to 77Lu -DOTATATE (177Lu-Oxodotreotide) and hence, can find applications in the same type of indications as this marketed drug. The authors claim that this drug shows remarkably higher uptake and retention in NET tumors.
A first pilot study aiming to evaluate the efficacy of a single low-dose treatment in patients with advanced neuroendocrine neoplasm (NEN) was performed and results were published in May 2018. 68Ga-DOTATATE was used to select and follow up the patients.